ProCE Banner Activity

Trigger Avoidance as a Basic Element in Atopic Dermatitis Management

Clinical Thought

Avoidance of triggering allergens and irritants is a core element of basic management, which is recommended for all atopic dermatitis (AD) severities. Read commentary by leading clinical experts to learn strategies for identifying and avoiding allergens.

Released: July 18, 2022

Expiration: July 17, 2023

No longer available for credit.



Victoria Garcia-Albea

Victoria Garcia-Albea, PNP, DCNP, MSN, BSN, PRN

Lahey Dermatology Nurse Practitioner Training Program
Lahey Hospital and Medical Center
Burlington, Massachusetts

Jonathan I. Silverberg

Jonathan I. Silverberg, MD, PhD, MPH

Associate Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC


This activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Provided by

ProCE Banner


Regeneron Pharmaceuticals

Sanofi Genzyme

Target Audience

NPs/PAs, Primary Care NPs/PAs, Pediatric NPs


Jonathan Silverberg, MD, MPH: consultant: AbbVie, Afyx, Aobiome, Arena, Asana, Aslan, BioMX, Biosion, Bluefin, Bodewell, Boehringer Ingelheim, Cara, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo, Luna, Menlo, Novartis, Optum, Pfizer, RAPT, Regeneron, Sanofi, Shaperon, Sidekick Health; fees for non-CME/CE services: AbbVie, Eli Lilly, Leo, Pfizer, Regeneron, Sanofi; funds for research support (paid to institution): Galderma, Pfizer.

Victoria Garcia-Albea, PNP, DCNP, MSN, BSN, PRN: consultant: Sanofi-Genzyme.

Tracey Piparo, PA-C, has no relevant financial relationships to disclose.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose.



Additional Information

Program Medium

This program has been made available online.